RT Journal Article
SR Electronic
T1 The Role of Frailty in Shaping Social Contact Patterns in Belgium, 2022-2023
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.10.24315233
DO 10.1101/2024.10.10.24315233
A1 Loedy, Neilshan
A1 Hermans, Lisa
A1 Bosschaert, Maikel
A1 Torneri, Andrea
A1 Hens, Niel
YR 2024
UL http://medrxiv.org/content/early/2024/10/10/2024.10.10.24315233.abstract
AB Social contact data are essential for understanding the spread of respiratory infectious diseases and designing effective prevention strategies. However, many studies often overlook the heterogeneity in mixing patterns among older age groups and individual frailty levels, assuming homogeneity across these sub-populations. This oversight may undermine non-pharmaceutical interventions by not targeting specific contact behaviours, potentially reducing their effectiveness in controlling disease. To address this gap, we conducted a contact survey in Flanders, Belgium (June 2022 to June 2023). Using this dataset, we reconstructed frailty-dependent contact matrices and developed a contact-based mathematical model that integrates frailty levels to investigate their impact on disease transmission dynamics. We collected data from 5,723 participants who recorded 31,375 contacts with distinct individuals. Contact patterns were observed to vary based on participants’ age and frailty levels, influenced by the locations of their interactions. Incorporating frailty levels into the mathematical model substantially alters the shape of epidemic curves and peak incidences. Such insights are crucial for designing tailored non-pharmaceutical interventions, indicating the need for similar data collection in different countries.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this study [study number: 215366] was provided by GSK. GSK was provided the opportunity to review a preliminary version of this publication for factual accuracy, but the authors are solely responsible for final content and interpretation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the Comite voor Medische Ethiek UHasselt (CME UHasselt) with Reference Number: CME2021/110.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.